ORDA - Online Research Data Archive 
    • Login
    View Item 
    •   ORDA Home
    • University Hospitals of Derby and Burton NHS Foundation Trust
    • Division of Women's and Children's Services
    • Paediatrics
    • View Item
    •   ORDA Home
    • University Hospitals of Derby and Burton NHS Foundation Trust
    • Division of Women's and Children's Services
    • Paediatrics
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    An audit of the effectiveness of PCSK9 inhibition in reducing cholesterol in patients attending lipid clinics

    Thumbnail
    Abstract
    Introduction: Evolocumab and alirocumab are monoclonal antibodies that inhibit PCSK-9 and reduce LDl-C. This audit assessed the effectiveness of PCSK9 inhibitor administration in patients attending lipid clinics at regional and local centres. Methods: Data from patients in treated in accord with NICE Technology Appraisals TA394 and TA396 was obtained from the lipid clinics at Guy's & St. Thomas' Hospitals and Queen's Hospital, Burton-on-Trent. All patients had undergone a cardiovascular assessment and lipid measurements. Results: The 75 patients were aged 61.1+/-12.1 (average+/-SD) years and 33% were female. The indications for prescription were Familial Hypercholesterolaemia (75%); intolerance to >3 statins (67%), coronary heart disease with LDL-C>4 mmol/L (33%); multivascular disease and LDL-C>3.50 mmol/L (26%) and other (9%). Scripts were issued for Evolocumab (140mg; n=52) and Alirocumab (n=17; 12 receiving 150 mg and 5 75 mg respectively). Data was available for 43 patients who had completed more than 3 months treatment. Pre-treatment total cholesterol (TC) was 7.94+/-2.37 mmol/L, LDL-cholesterol (LDLC) 5.44+/-1.90 mmol/L, triglycerides (TG) median 1.89 (range 0.5-34.8) mmol/l and HDL-C 1.39+/-0.38 mmol/L. Post-treatment levels were TC 5.91+/-2.45 mmol/l, LDL-C 3.30+/-1.63 mmol/L, TG 1.67 (0.63-27.8) mmol/l and HDLC 1.42+/-0.4 mmol/L. The average reductions in lipids were a median 41 (range 90 to-35) %; (2.07+/-1.17 mmol/L) for LDL-C, and 27 (range 52 to-19)% (2.10+/-1.48 mmol/L) for TC respectively. Discontinuations were reported in 7 patients and 3 reported adverse effects (myalgia). A <25% LDL-C response was seen in 19% of patients. Conclusion: Treatment with PCSK9 inhibitor therapy is associated with a 41% reduction in LDL-C in qualifying patients who tolerate the medication but 19% fail to respond.
    URI
    https://orda.derbyhospitals.nhs.uk/handle/123456789/1540
    Collections
    • Paediatrics [27]
    Date
    2017
    Author
    Reynolds, Tim
    Show full item record

    copyright © 2017  Derby Teaching Hospitals NHS Foundation Trust
    Contact Us | Send Feedback
    Powered by KnowledgeArc
     

     

    Browse

    All of ORDACommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    Researcher Profiles

    Researchers

    My Account

    Login

    copyright © 2017  Derby Teaching Hospitals NHS Foundation Trust
    Contact Us | Send Feedback
    Powered by KnowledgeArc